1,023 results on '"Tsushima T"'
Search Results
2. Measurement and comparison of individual external doses of high-school students living in Japan, France, Poland and Belarus -- the 'D-shuttle' project --
3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
5. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
6. 389P Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
7. 1211P A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)
8. 446TiP Randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI for chemorefractory metastatic colorectal cancer (mCRC): ROBiTS/JCOG2014
9. 1241P Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: Tolerability results and antitumor activity in esophageal carcinoma
10. P-95 Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study
11. 135 A Case of Late-Onset Hypogonadism Syndrome with Rapidly Elevated Prostate Specific Antigen
12. PD-013 Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE)
13. P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study
14. Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases
15. Epidermal growth factor in urine from patients with bladder cancer
16. Chromosomal numerical aberrations of exfoliated cells in the urine detected by fluorescence in situ hybridization: clinical implication for the detection of bladder cancer
17. New method for quantitative assessment of airway calibre using a stereovision fibreoptic bronchoscope
18. SAFETY AND EFFICACY OF PROTON-BEAM RADIATION THERAPY FOR PATIENTS WITH LOCALLY RECURRENT RECTAL CANCER
19. EFFICACY AND SAFETY OF CHEMORADIOTHERAPY FOR PATIENTS WITH LOCOREGIONAL LYMPH NODE RECURRENCE OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA
20. CORRELATION BETWEEN THE EFFECTS OF FIRST-LINE CHEMOTHERAPY AND SURVIVAL TIME FROM SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
21. P-356 phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study
22. P-69 Efficacy and safety of S-1 following gemcitabine with cisplatin for biliary tract cancer
23. Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
24. Temperature dependence of the Faraday effect in Rh4+-substituted magnetic garnets
25. Charge transfer-originated large Faraday rotation in Rh4+-substituted magnetic garnets
26. Thyroid ultrasonography related to clinical and laboratory findings in patients with silent thyroiditis
27. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer
28. A Case of late-onset hypogonadism syndrome with rapidly elevated prostate specific antigen
29. A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up
30. Humoral and cellular immune responses to NY-ESO-1 in advanced prostate cancer patients
31. Quantitative analysis of REIC gene expression in renal cell carcinoma
32. Two times instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder tumours: a prospective, randomized controlled study
33. Simultaneous vs. sequential combination in situ gene therapy using a novel mouse model of metastatic prostate cancer
34. The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer
35. Primary non-Hodgkin lymphoma of the ureter
36. PF635 SERUM ERYTHROPOIETIN IS A PREDICTIVE FACTOR OF RENAL REVERSIBILITY IN RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS
37. Mutual waterworks support system based on Japanese earthquake disaster experience
38. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): A post hoc analysis of the WJOG4407G phase III study
39. Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer
40. Receptor-Stimulated System Mediated Interactions of Neuropeptides in GH3 Cells
41. The Effect of Pressure on The Raman Spectra in Trigonal Se and Te
42. Carbon content dependence of the spin reorientation in Er2Fe17Cx
43. 1772P - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
44. A Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410)
45. Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors
46. A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies
47. Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07)
48. Propagation and some physiological effects of Citrus bark cracking viroid and Apple fruit crinkle viroid in multiple infected hop (Humulus lupulus L.)
49. 218TiP A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE)
50. Risk factors for esophageal fistula in esophageal squamous cell carcinoma invading adjacent organs (T4b) treated with definitive chemoradiotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.